Live respiratory syncytial virus (RSV) vaccine candidate containing stabilized temperature-sensitivity mutations is highly attenuated in RSV-seronegative infants and children

Journal of Infectious Diseases

Volumn 217, Issue 9, 2018, Pages 1338-1346

  Buchholz, Ursula J ^a   Cunningham, Coleen K ^f   Muresan, Petronella ^h   Gnanashanmugam, Devasena ^b   Sato, Paul ^b   Siberry, George K ^c   Rexroad, Vivian ^d   Valentine, Megan ^g   Perlowski, Charlotte ^g   Schappell, Elizabeth ^e   Thumar, Bhagvinji ^e   Luongo, Cindy ^a   Barr, Emily ⁱ   Aziz, Mariam ^j   Yogev, Ram ^k   Spector, Stephen A ^l   Collins, Peter L ^a   McFarland, Elizabeth J ⁱ   Karron, Ruth A ^e  

^a Laboratory of Clinical Infectious Diseases   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^d JOHNS HOPKINS HOSPITAL   (United States)

^e JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^f DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g FAMILY HEALTH INTERNATIONAL   (United States)

^h HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

ⁱ UNIVERSITY OF COLORADO   (United States)

^j RUSH UNIVERSITY MEDICAL CENTER   (United States)

^k NORTHWESTERN UNIVERSITY   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

Pediatric vaccine; Recombinant live attenuated vaccine; Respiratory syncytial virus; Respiratory virus infection; Reverse genetics

Indexed keywords

LIVE VACCINE; NEUTRALIZING ANTIBODY; PLACEBO; RESPIRATORY SYNCYTIAL VIRUS VACCINE; VIRUS ANTIBODY;

ACUTE OTITIS MEDIA; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; CHILD; CONFERENCE PAPER; CONTROLLED STUDY; COUGHING; DRUG TOLERABILITY; FEMALE; FEVER; GENETIC STABILITY; HOARSENESS; HUMAN; HUMAN EXPERIMENT; HUMAN RESPIRATORY SYNCYTIAL VIRUS; INFANT; MALE; NASAL LAVAGE FLUID; NORMAL HUMAN; PATIENT MONITORING; PHARYNGITIS; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; RHINORRHEA; SINGLE DRUG DOSE; TEMPERATURE SENSITIVE MUTANT; UPPER RESPIRATORY TRACT INFECTION; VACCINE IMMUNOGENICITY; VIRUS ATTENUATION; VIRUS INFECTIVITY; VIRUS SHEDDING; VIRUS TRANSMISSION; BLOOD; CLINICAL TRIAL; GENETICS; IMMUNOLOGY; MULTICENTER STUDY; MUTATION; RESPIRATORY SYNCYTIAL VIRUS INFECTION; VIRUS REPLICATION;

ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; FEMALE; HUMANS; IMMUNOGENICITY, VACCINE; INFANT; MALE; MUTATION; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; VACCINES, ATTENUATED; VIRUS REPLICATION;

EID: 85050745387     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiy066     Document Type: Conference Paper

References (33)

1. Díez-Domingo J, Pérez-Yarza EG, Melero JA, et al. Social, economic, and health impact of the respiratory syncytial virus: a systematic search. BMC Infect Dis 2014; 14:544.
2. Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010; 375:1545–55.
3. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998; 102:531–7.
4. Kim HW, Canchola JG, Brandt CD, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969; 89:422–34.
5. Caballero MT, Jones MH, Karron RA, et al.; RSV & Pediatric Asthma Working Group. The impact of respiratory syncytial virus disease prevention on pediatric asthma. Pediatr Infect Dis J 2016; 35:820–2.
6. Wright PF, Karron RA, Belshe RB, et al. The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines. Vaccine 2007; 25:7372–8.
7. Karron RA, Luongo C, Thumar B, et al. A gene deletion that up-regulates viral gene expression yields an attenuated RSV vaccine with improved antibody responses in children. Sci Transl Med 2015; 7:312ra175.
8. Karron RA, Wright PF, Belshe RB, et al. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J Infect Dis 2005; 191:1093–104.
9. Karron RA, Wright PF, Crowe JE Jr, et al. Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children. J Infect Dis 1997; 176:1428–36.
10. Malkin E, Yogev R, Abughali N, et al. Safety and immunogenicity of a live attenuated RSV vaccine in healthy RSV-seronegative children 5 to 24 months of age. PLoS One 2013; 8:e77104.
11. Wright PF, Karron RA, Belshe RB, et al. Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J Infect Dis 2000; 182:1331–42.
12. Wright PF, Karron RA, Madhi SA, et al. The interferon antagonist NS2 protein of respiratory syncytial virus is an important virulence determinant for humans. J Infect Dis 2006; 193:573–81.
13. Karron RA, Buchholz UJ, Collins PL. Live-attenuated respiratory syncytial virus vaccines. Curr Top Microbiol Immunol 2013; 372:259–84.
14. Whitehead SS, Juhasz K, Firestone CY, Collins PL, Murphy BR. Recombinant respiratory syncytial virus (RSV) bearing a set of mutations from cold-passaged RSV is attenuated in chimpanzees. J Virol 1998; 72:4467–71.
15. Crowe JE Jr, Bui PT, Davis AR, Chanock RM, Murphy BR. A further attenuated derivative of a cold-passaged temperature-sensitive mutant of human respiratory syncytial virus retains immunogenicity and protective efficacy against wild-type challenge in seronegative chimpanzees. Vaccine 1994; 12:783–90.
16. Whitehead SS, Firestone CY, Collins PL, Murphy BR. A single nucleotide substitution in the transcription start signal of the M2 gene of respiratory syncytial virus vaccine candidate cpts248/404 is the major determinant of the temperature-sensitive and attenuation phenotypes. Virology 1998; 247:232–9.
17. Whitehead SS, Firestone CY, Karron RA, et al. Addition of a missense mutation present in the L gene of respiratory syncytial virus (RSV) cpts530/1030 to RSV vaccine candidate cpts248/404 increases its attenuation and temperature sensitivity. J Virol 1999; 73:871–7.
18. Bukreyev A, Whitehead SS, Murphy BR, Collins PL. Recombinant respiratory syncytial virus from which the entire SH gene has been deleted grows efficiently in cell culture and exhibits site-specific attenuation in the respiratory tract of the mouse. J Virol 1997; 71:8973–82.
19. Luongo C, Winter CC, Collins PL, Buchholz UJ. Increased genetic and phenotypic stability of a promising live-attenuated respiratory syncytial virus vaccine candidate by reverse genetics. J Virol 2012; 86:10792–804.
20. Luongo C, Yang L, Winter CC, et al. Codon stabilization analysis of the “248” temperature sensitive mutation for increased phenotypic stability of respiratory syncytial virus vaccine candidates. Vaccine 2009; 27:5667–76.
21. Luongo C, Winter CC, Collins PL, Buchholz UJ. Respiratory syncytial virus modified by deletions of the NS2 gene and amino acid S1313 of the L polymerase protein is a temperature-sensitive, live-attenuated vaccine candidate that is phenotypically stable at physiological temperature. J Virol 2013; 87:1985–96.
22. Collins PL, Hill MG, Camargo E, Grosfeld H, Chanock RM, Murphy BR. Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5’ proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development. Proc Natl Acad Sci U S A 1995; 92:11563–7.
23. Coates HV, Alling DW, Chanock RM. An antigenic analysis of respiratory syncytial virus isolates by a plaque reduction neutralization test. Am J Epidemiol 1966; 83:299–313.
24. Smith G, Raghunandan R, Wu Y, et al. Respiratory syncytial virus fusion glycoprotein expressed in insect cells form protein nanoparticles that induce protective immunity in cotton rats. PLoS One 2012; 7:e50852.
25. Karron RA, Talaat K, Luke C, et al. Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults. Vaccine 2009; 27:4953–60.
26. Johnson PR Jr, Olmsted RA, Prince GA, et al. Antigenic relatedness between glycoproteins of human respiratory syncytial virus subgroups A and B: evaluation of the contributions of F and G glycoproteins to immunity. J Virol 1987; 61:3163–6.
27. Connors M, Collins PL, Firestone CY, et al. Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia–RSV recombinants or RSV. Vaccine 1992; 10:475–84.
28. Murphy BR, Sotnikov AV, Lawrence LA, Banks SM, Prince GA. Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization. Vaccine 1990; 8:497–502.
29. Acosta PL, Caballero MT, Polack FP. Brief history and characterization of enhanced respiratory syncytial virus disease. Clin Vaccine Immunol 2015; 23:189–95.
30. Ponnuraj EM, Springer J, Hayward AR, Wilson H, Simoes EA. Antibody-dependent enhancement, a possible mechanism in augmented pulmonary disease of respiratory syncytial virus in the Bonnet monkey model. J Infect Dis 2003; 187:1257–63.
31. Gershwin LJ, Schelegle ES, Gunther RA, et al. A bovine model of vaccine enhanced respiratory syncytial virus pathophysiology. Vaccine 1998; 16:1225–36.
32. Prince GA, Curtis SJ, Yim KC, Porter DD. Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine. J Gen Virol 2001; 82:2881–8.
33. McFarland EJ, Karron R, Muresan P, et al. Live-attenuated respiratory syncytial virus vaccine candidate with deletion of RNA synthesis regulatory protein M2-2 is highly immunogenic in children. J Infect Dis. 2018; 217:1347–55.